Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40947367.
- Also identified by DOI 10.1016/j.eururo.2025.08.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Results from the EMBARK trial reshape the treatment paradigm for high-risk biochemical recurrence of prostate cancer. EMBARK data support the use of androgen receptor pathway inhibitors combined with metastasis-directed therapy in a personalized, multidisciplinary care approach for this subset of patients.
Medical subject headings
- Prostatic Neoplasms
- Androgen Receptor Antagonists
- Neoplasm Recurrence, Local
- Androgen Antagonists